Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
| dc.contributor.author | Vergote, I. | en |
| dc.contributor.author | Himmelmann, A. | en |
| dc.contributor.author | Frankendal, B. | en |
| dc.contributor.author | Scheistroen, M. | en |
| dc.contributor.author | Vlachos, K. | en |
| dc.contributor.author | Trope, C. | en |
| dc.date.accessioned | 2015-11-24T19:13:54Z | |
| dc.date.available | 2015-11-24T19:13:54Z | |
| dc.identifier.issn | 0090-8258 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21239 | |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Altretamine/adverse effects/*therapeutic use | en |
| dc.subject | Carboplatin/*therapeutic use | en |
| dc.subject | Cisplatin/*therapeutic use | en |
| dc.subject | Drug Resistance | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Ovarian Neoplasms/*drug therapy | en |
| dc.title | Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer | en |
| heal.abstract | A total of 61 patients with recurrent or persistent clinically measurable platin-resistant epithelial ovarian carcinoma were treated with 260 mg/m2 oral hexamethylmelamine daily for 14 days, repeated at 4-week intervals. Platin resistance was defined as progression or stable disease during cis- or carboplatin treatment (used alone or in combination with other drugs), or relapse within 6 months after the end of that therapy. Fifty patients were evaluable for response and 57 for toxicity. The objective response rate was 14% (3 complete and 4 partial responses). The response rate was higher in patients with relapse within 6 months than in patients with progression or stable disease on platin-based therapy. This observation underscores the importance of defining response and time to progression after first-line chemotherapy. The median duration of response was 8 months and the median survival in responding patients was 9+ months versus 5 months for patients with progression on hexamethylmelamine. Nausea and vomiting requiring antiemetic treatment occurred in 8 (14%) patients and reversible peripheral neuropathy in 3 patients. Two patients developed agitation, insomnia, and depression during hexamethylmelamine therapy. In conclusion, the 14% objective response rate and the occurrence of complete responses with oral hexamethylmelamine treatment in a group of ovarian cancer patients with true platin resistance are noteworthy. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/1473738 | - |
| heal.journalName | Gynecol Oncol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 1992 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: